TITLE

Gruenenthal to Present at 2012 BIO Intl Convention on June 20 2012, in Boston MA, US

PUB. DATE
June 2012
SOURCE
Biomedical Market Newsletter;6/18/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Proceeding
ABSTRACT
The article offers information on the 2012 BIO Intl Convention to be held in Boston, Massachusetts on June 20, 2012 attended by the Gruenenthal Group which is a research-based pharmaceutical company.
ACCESSION #
77449196

 

Related Articles

  • Labopharm completes distribution and supply agreement with Grunenthal.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p12 

    The article reports on the distribution and supply agreement between Labopharm, a Canadian pharmaceutical company and Grunenthal, a german pharmaceutical company. Under the concord terms, Grunenthal has the right to commercialize and sell Labopharm's tramadol-acetaminophen formulation in the...

  • Grunenthal/J&J's new opioid analgesic outshines blockbuster painkiller OxyContin.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p14 

    The article focuses on the opioid analgesic tapentadol extended-release (ER) from Grunenthal GmbH and Johnson & Johnson. Results of a Phase III study show that the drug is effective in treating chronic low back pain with improved gastrointestinal tolerability. It says that the dual mode of...

  • Other News To Note.  // BioWorld Today;2/10/2011, Vol. 22 Issue 28, p5 

    This section offers news briefs on the biotechnology industry. A notice of noncompliance was received by AMAG Pharmaceuticals Inc. from Health Canada regarding its drug submission for Feraheme for iron deficiency anemia. Worldwide development and commercialization rights have been acquired by...

  • Straw drug delivery.  // Pharmaceutical Technology Europe;Jan2006, Vol. 18 Issue 1, p57 

    The article reports on the development of a novel drug delivery method that uses a straw to help mask the taste of antibiotic treatments. The product is aimed at children and has been produced by a German pharmaceutical company Grunenthal GmbH. The product called as clarosip is actually a...

  • APS 2010: opioid safety and tolerability analyses take center stage.  // PharmaWatch: Monthly Review;Jul2010, Vol. 9 Issue 7, p15 

    The article presents data unveiled by Johnson & Johnson (J & J) and King Pharmaceuticals Inc. at the American Pain Society meeting in the U.S. in 2010 is presented. During the event, J & J and Grunenthal GmbH unveiled the long-term data of its advanced candidate tapentadol ER. Morever, King...

  • Labopharm completes distribution and supply agreement with Grunenthal.  // PharmaWatch: CNS;Dec2009, Vol. 8 Issue 12, p14 

    The article reports on the completion of the distribution and supply agreement by Labopharm Inc., a Canadian pharmaceutical company with Grunenthal GmbH, a German pharmaceutical company. It states that the agreement provides Grunenthal the exclusive right to market twice-daily...

  • Grunenthal Ltd.  // British Journal of Community Nursing;Dec2005, Vol. 10 Issue 12, p580 

    The article reports that pharmaceutical company Grünenthal GmbH has launched a new device for delivering an antibiotic to children. Clarossip® is a drinking straw that contains clarithromycin in one of the three doses depending on the child's age and weight. This new device will take the...

  • Bitter pill for WDR. Kirschbaum, Erik // Variety;12/11/2006, Vol. 405 Issue 4, p7 

    The article reports that Westdeutscher Rundfunk (WDR) is fighting a restraining order blocking it from showing "Eine einzige Tablette," a film about the thalidomide scandal in the 1960s on German television. A court ruled against WDR in favor of Grunenthal, the drug company that manufactured the...

  • IN BRIEF.  // Engineer (00137758);11/14/2005, Vol. 293 Issue 7688, p7 

    The article presents news briefs related to technology in the United States. Large petrol service stations will be fitted with fume control equipment in a bid to halve emissions,recycle them into fuel and reduce smog. A UAV whose capabilities can be tailored for each mission is being developed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics